Patents Assigned to Chiesi Farmaceutici S.p.A.
  • Triazolinone compounds as HNE inhibitors
    Patent number: 9890169
    Abstract: Triazolinone compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: February 13, 2018
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta Armani, Carmelida Capaldi
  • Particle size reduction of an antimuscarinic compound
    Patent number: 9889094
    Abstract: A stable crystalline micronized particulate of a glycopyrronium salt may be prepared by suspending the drug in a water-immiscible anti-solvent in which the drug has little or no solubility and micronizing the suspension. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 13, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Irene Pasquali, Andrea Casazza, Elena Losi, Mark Saunders
  • COMBINATION THERAPY FOR COPD
    Publication number: 20180028439
    Abstract: Aerosol formulations comprising glycopyrronium bromide, formoterol or a salt thereof, and beclometasone dipropionate are useful for the prevention or treatment of moderate/severe chronic obstructive pulmonary disease.
    Type: Application
    Filed: July 28, 2017
    Publication date: February 1, 2018
    Applicant: CHIESI FARMACEUTICI S.p.A
    Inventors: Mario SCURI, Pierfrancesco Coli, Giuseppe DELMONTE
  • AEROSOL FORMULATION FOR COPD
    Publication number: 20180021301
    Abstract: The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions.
    Type: Application
    Filed: September 7, 2017
    Publication date: January 25, 2018
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • AMINOESTER DERIVATIVES
    Publication number: 20180016265
    Abstract: Compounds of formula (I) are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta ARMANI, Gabriele Amari, Wesley Blackaby, Herve Van De Poel, Charles Baker-Glenn, Naimisha Trivedi
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20180016267
    Abstract: Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 18, 2018
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Pyrimidinone compounds which are HNE inhibitors
    Patent number: 9868740
    Abstract: This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: January 16, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • NOVEL COMPOUNDS
    Publication number: 20180009787
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • Compounds
    Patent number: 9862706
    Abstract: Imidazolone and pyrazolone derivatives of formula (I) described herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 9, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Carmelida Capaldi, Elisabetta Armani, Andrew Stephen Robert Jennings
  • Isoxazolidine derivatives
    Patent number: 9845337
    Abstract: Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 19, 2017
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Eleonora Ghidini, Andrea Rizzi
  • NOVEL COMPOUNDS
    Publication number: 20170342056
    Abstract: Imidazolone and pyrazolone derivatives of formula (I) described herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Carmelida CAPALDI, Elisabetta ARMANI, Andrew Stephen Robert JENNINGS
  • NOVEL COMPOUNDS
    Publication number: 20170340611
    Abstract: Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew HEALD, Andrew Stephen Robert JENNINGS, Carmelida CAPALDI, Elisabetta ARMANI
  • AMINOESTER DERIVATIVES
    Publication number: 20170340616
    Abstract: Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta Armani, Gabriele Gabriele, Carmelida Capaldi, Wesley Blackaby, Ian Linney, Hervé Van De Poël, Charles Baker-Glenn, Naimisha Trivedi
  • Pyrimidinone compounds as human neutrophil elastase inhibitors
    Patent number: 9828382
    Abstract: Pyrimidone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and condition in which HNE is implicated.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 28, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
    Patent number: 9808422
    Abstract: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of inflammatory and/or obstructive airways diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: November 7, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Irene Pasquali, Rossella Musa, Francesca Schiaretti, Azita Askey-Sarvar
  • Aminoester derivatives
    Patent number: 9809582
    Abstract: Compounds of formula (I) are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 7, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Wesley Blackaby, Herve Van De Poel, Charles Baker-Glenn, Naimisha Trivedi
  • Compounds
    Patent number: 9802919
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: October 31, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING THE SAME
    Publication number: 20170304345
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Panna DUTTA, Adel RAFAI FAR, Min DING, Rajeshwar MOTHERAM
  • AEROSOL INHALATION DEVICE
    Publication number: 20170281885
    Abstract: Actuators for a pressurised metered dose inhalers containing (a) a housing adapted to receive an aerosol canister containing a pressurised medicament formulation, (b) a nozzle block defining the receptacle for the aerosol canister valve stem, the expansion chamber or sump, the nozzle channel its external aperture, and (c) a mouthpiece portion comprising a central rounded opening of a defined width and distance from the nozzle aperture and a cylindrical recess, whose central axis is aligned with the central longitudinal axis of the mouthpiece portion and with the central longitudinal axis of the nozzle channel, provide a significant reduction in the non-respirable coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator rather than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 5, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Diego Copelli, Andrea Casazza
  • Aminoester derivatives
    Patent number: 9763924
    Abstract: Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 19, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Carmelida Capaldi, Wesley Blackaby, Ian Linney, Hervé Van De Poël, Charles Baker-Glenn, Naimisha Trivedi